Results

1–10 of 16 results for Pegcetacoplan

Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2023
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2023
Retinal Tissue Preservation With Intravitreal Pegcetacoplan in Patients With Geographic Atrophy
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2023
Effect of Pegcetacoplan on Photoreceptor and Retinal Pigment Epithelium Integrity in Geographic Atrophy in the Phase 3 Trials and GALE Extension Study
Ursula M. Schmidt-Erfurth, MD
Annual Meeting Talks
2023
Long-Term Efficacy of Pegcetacoplan in Patients With Geographic Atrophy
Nathan C. Steinle, MD
Annual Meeting Talks
2023
Expert Panel: Pegcetacoplan Safety
Andre J. Witkin, MD
David A. Eichenbaum, MD, FASRS
Samuel Anthony Minaker, MD, MSc
Janani Singaravelu, MS, MD
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2024
Expert Panel: AI
Mark S. Humayun, MD, PhD
Devinder S Chauhan, MD FRCOphth FRANZCO
Ursula M. Schmidt-Erfurth, MD
Jennifer I. Lim, MD, FARVO, FASRS
Royce WS Chen, MD
Annual Meeting Talks
2024
Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2024
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025
Pegcetacoplan Safety: Panel Recap
Andre J. Witkin, MD
Updates from the Field
2024